Navidea Receives $1.1Million PDUFA Filing Fee Refund for Award of Orphan Drug Status; Platinum Partners Reaffirms Commitment to Line of Credit Nov 11, 2014
Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European Association of Nuclear Medicine and European Society of Surgical Oncology Meetings Oct 30, 2014
Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014 Oct 29, 2014
FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors Oct 15, 2014
Navidea to Participate in the BTIG Emerging Technologies in Healthcare Diagnostics Investor Conference September 30th Sep 29, 2014
Navidea’s Lymphoseek® Recommended by CHMP for European Approval in Sentinel Lymph Node Detection for Melanoma, Breast and Certain Head and Neck Cancers Sep 26, 2014
Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical Cancer Sep 23, 2014
Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers Sep 18, 2014
